1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. Ca Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
2
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. Ca Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
3
|
Van Cutsem E, Sagaert X, Topal B,
Haustermans K and Prenen H: Gastric cancer. Lancet. 388:2654–2664.
2016. View Article : Google Scholar : PubMed/NCBI
|
4
|
Wang FH, Shen L, Li J, Zhou ZW, Liang H,
Zhang XT, Tang L, Xin Y, Jin J, Zhang YJ, et al: The Chinese
society of clinical oncology (CSCO): Clinical guidelines for the
diagnosis and treatment of gastric cancer. Cancer Commun (Lond).
39:102019. View Article : Google Scholar : PubMed/NCBI
|
5
|
Yamada Y, Higuchi K, Nishikawa K, Gotoh M,
Fuse N, Sugimoto N, Nishina T, Amagai K, Chin K, Niwa Y, et al:
Phase III study comparing oxaliplatin plus S-1 with cisplatin plus
S-1 in chemotherapy-naive patients with advanced gastric cancer.
Ann Oncol. 26:141–148. 2015. View Article : Google Scholar : PubMed/NCBI
|
6
|
Quintanilha JCF, Saavedra KF, Visacri MB,
Moriel P and Salazar LA: Role of epigenetic mechanisms in
cisplatin-induced toxicity. Crit Rev Oncol Hematol. 137:131–142.
2019. View Article : Google Scholar : PubMed/NCBI
|
7
|
Berman AY, Motechin RA, Wiesenfeld MY and
Holz MK: The therapeutic potential of resveratrol: A review of
clinical trials. NPJ Precis Oncol. 1:352017. View Article : Google Scholar : PubMed/NCBI
|
8
|
Bonnefont-Rousselot D: Resveratrol and
cardiovascular diseases. Nutrients. 8:2502016. View Article : Google Scholar
|
9
|
Ahmed T, Javed S, Javed S, Tariq A, Šamec
D, Tejada S, Nabavi SF, Braidy N and Nabavi SM: Resveratrol and
Alzheimers disease: Mechanistic insights. Mol Neurobiol.
54:2622–2635. 2017. View Article : Google Scholar : PubMed/NCBI
|
10
|
Nunes S, Danesi F, Del Rio D and Silva P:
Resveratrol and inflammatory bowel disease: The evidence so far.
Nutr Res Rev. 31:85–97. 2018. View Article : Google Scholar : PubMed/NCBI
|
11
|
Wong RHX and Howe PRC: Resveratrol
counteracts insulin resistance-potential role of the circulation.
Nutrients. 10:11602018. View Article : Google Scholar
|
12
|
Jiang Z, Chen K, Cheng L, Yan B, Qian W,
Cao J, Li J, Wu E, Ma Q and Yang W: Resveratrol and cancer
treatment: Updates. Ann N Y Acad Sci. 1403:59–69. 2017. View Article : Google Scholar : PubMed/NCBI
|
13
|
Zulueta A, Caretti A, Signorelli P and
Ghidoni R: Resveratrol: A potential challenger against gastric
cancer. World J Gastroenterol. 21:10636–10643. 2015. View Article : Google Scholar : PubMed/NCBI
|
14
|
Zhou HB, Chen JJ, Wang WX, Cai JT and Du
Q: Anticancer activity of resveratrol on implanted human primary
gastric carcinoma cells in nude mice. World J Gastroenterol.
11:280–284. 2005. View Article : Google Scholar : PubMed/NCBI
|
15
|
Yang Z, Xie Q, Chen Z, Ni H, Xia L, Zhao
Q, Chen Z and Chen P: Resveratrol suppresses the invasion and
migration of human gastric cancer cells via inhibition of
MALAT1-mediated epithelial-to-mesenchymal transition. Exp Ther Med.
17:1569–1578. 2019.PubMed/NCBI
|
16
|
Wang M and Kaufman RJ: Protein misfolding
in the endoplasmic reticulum as a conduit to human disease. Nature.
529:326–335. 2016. View Article : Google Scholar : PubMed/NCBI
|
17
|
Hetz C and Papa FR: The unfolded protein
response and cell fate control. Mol Cell. 69:169–181. 2018.
View Article : Google Scholar : PubMed/NCBI
|
18
|
Kim C and Kim B: Anti-cancer natural
products and their bioactive compounds inducing ER stress-mediated
apoptosis: A review. Nutrients. 10:10212018. View Article : Google Scholar
|
19
|
Park JW, Woo KJ, Lee JT, Lim JH, Lee TJ,
Kim SH, Choi YH and Kwon TK: Resveratrol induces pro-apoptotic
endoplasmic reticulum stress in human colon cancer cells. Oncol
Rep. 18:1269–1273. 2007.PubMed/NCBI
|
20
|
Gwak H, Kim S, Dhanasekaran DN and Song
YS: Resveratrol triggers ER stress-mediated apoptosis by disrupting
N-linked glycosylation of proteins in ovarian cancer cells. Cancer
Lett. 371:347–353. 2016. View Article : Google Scholar : PubMed/NCBI
|
21
|
Heo JR, Kim SM, Hwang KA, Kang JH and Choi
KC: Resveratrol induced reactive oxygen species and endoplasmic
reticulum stressmediated apoptosis, and cell cycle arrest in the
A375SM malignant melanoma cell line. Int J Mol Med. 42:1427–1435.
2018.PubMed/NCBI
|
22
|
Chou TC: Drug combination studies and
their synergy quantification using the Chou-Talalay method. Cancer
Res. 70:440–446. 2010. View Article : Google Scholar : PubMed/NCBI
|
23
|
Gu ML, Wang YM, Zhou XX, Yao HP, Zheng S,
Xiang Z and Ji F: An inhibitor of the acetyltransferases CBP/p300
exerts antineoplastic effects on gastrointestinal stromal tumor
cells. Oncol Rep. 36:2763–2770. 2016. View Article : Google Scholar : PubMed/NCBI
|
24
|
Wang YM, Gu ML, Meng FS, Jiao WR, Zhou XX,
Yao HP and Ji F: Histone acetyltransferase p300/CBP inhibitor C646
blocks the survival and invasion pathways of gastric cancer cell
lines. Int J Oncol. 51:1860–1868. 2017. View Article : Google Scholar : PubMed/NCBI
|
25
|
Bahar E, Kim H and Yoon H: ER
stress-mediated signaling: Action potential and ca(2+) as key
players. Int J Mol Sci. 17:15582016. View Article : Google Scholar
|
26
|
Wagner AD, Syn NL, Moehler M, Grothe W,
Yong WP, Tai BC, Ho J and Unverzagt S: Chemotherapy for advanced
gastric cancer. Cochrane Database Syst Rev.
8:CD0040642017.PubMed/NCBI
|
27
|
Athar M, Back JH, Kopelovich L, Bickers DR
and Kim AL: Multiple molecular targets of resveratrol:
Anti-carcinogenic mechanisms. Arch Biochem Biophys. 486:95–102.
2009. View Article : Google Scholar : PubMed/NCBI
|
28
|
Lin SR, Chang CH, Hsu CF, Tsai MJ, Cheng
H, Leong MK, Sung PJ, Chen JC and Weng CF: Natural compounds as
potential adjuvants to cancer therapy: Preclinical evidence. Br J
Pharmacol. 177:1409–1423. 2020. View Article : Google Scholar : PubMed/NCBI
|
29
|
Martínez-Martínez D, Soto A, Gil-Araujo B,
Gallego B, Chiloeches A and Lasa M: Resveratrol promotes apoptosis
through the induction of dual specificity phosphatase 1 and
sensitizes prostate cancer cells to cisplatin. Food Chem Toxicol.
124:273–279. 2019. View Article : Google Scholar : PubMed/NCBI
|
30
|
Li W, Shi Y, Wang R, Pan L, Ma L and Jin
F: Resveratrol promotes the sensitivity of small-cell lung cancer
H446 cells to cisplatin by regulating intrinsic apoptosis. Int J
Oncol. 53:2123–2130. 2018.PubMed/NCBI
|
31
|
Ma L, Li W, Wang R, Nan Y, Wang Q, Liu W
and Jin F: Resveratrol enhanced anticancer effects of cisplatin on
non-small cell lung cancer cell lines by inducing mitochondrial
dysfunction and cell apoptosis. Int J Oncol. 47:1460–1468. 2015.
View Article : Google Scholar : PubMed/NCBI
|
32
|
Liu Z, Peng Q, Li Y and Gao Y: Resveratrol
enhances cisplatin-induced apoptosis in human hepatoma cells via
glutamine metabolism inhibition. BMB Rep. 51:474–479. 2018.
View Article : Google Scholar : PubMed/NCBI
|
33
|
Cubillos-Ruiz JR, Bettigole SE and
Glimcher LH: Tumorigenic and immunosuppressive effects of
endoplasmic reticulum stress in cancer. Cell. 168:692–706. 2017.
View Article : Google Scholar : PubMed/NCBI
|
34
|
Corazzari M, Gagliardi M, Fimia GM and
Piacentini M: Endoplasmic reticulum stress, unfolded protein
response, and cancer cell fate. Front Oncol. 7:782017. View Article : Google Scholar : PubMed/NCBI
|
35
|
Limonta P, Moretti RM, Marzagalli M,
Fontana F, Raimondi M and Montagnani Marelli M: Role of endoplasmic
reticulum stress in the anticancer activity of natural compounds.
Int J Mol Sci. 20:9612019. View Article : Google Scholar
|
36
|
Urra H, Dufey E, Avril T, Chevet E and
Hetz C: Endoplasmic reticulum stress and the hallmarks of cancer.
Trends Cancer. 2:252–262. 2016. View Article : Google Scholar : PubMed/NCBI
|
37
|
Rao RV, Ellerby HM and Bredesen DE:
Coupling endoplasmic reticulum stress to the cell death program.
Cell Death Differ. 11:372–380. 2004. View Article : Google Scholar : PubMed/NCBI
|
38
|
Gu S, Chen C, Jiang X and Zhang Z:
ROS-mediated endoplasmic reticulum stress and mitochondrial
dysfunction underlie apoptosis induced by resveratrol and arsenic
trioxide in A549 cells. Chem Biol Interact. 245:100–109. 2016.
View Article : Google Scholar : PubMed/NCBI
|
39
|
Chow SE, Kao CH, Liu YT, Cheng ML, Yang
YW, Huang YK, Hsu CC and Wang JS: Resveratrol induced ER expansion
and ER caspase-mediated apoptosis in human nasopharyngeal carcinoma
cells. Apoptosis. 19:527–541. 2014. View Article : Google Scholar : PubMed/NCBI
|
40
|
Otto T and Sicinski P: Cell cycle proteins
as promising targets in cancer therapy. Nat Rev Cancer. 17:93–115.
2017. View Article : Google Scholar : PubMed/NCBI
|
41
|
Shin KO, Park NY, Seo CH, Hong SP, Oh KW,
Hong JT, Han SK and Lee YM: Inhibition of sphingolipid metabolism
enhances resveratrol chemotherapy in human gastric cancer cells.
Biomol Ther (Seoul). 20:470–476. 2012. View Article : Google Scholar : PubMed/NCBI
|
42
|
Suttie SA, Park KG and Smith TA:
[18F]2-fluoro-2-deoxy-D-glucose incorporation by AGS gastric
adenocarcinoma cells in vitro during response to epirubicin,
cisplatin and 5-fluorouracil. Br J Cancer. 97:902–909. 2007.
View Article : Google Scholar : PubMed/NCBI
|
43
|
Satyanarayana A and Kaldis P: Mammalian
cell-cycle regulation: Several Cdks, numerous cyclins and diverse
compensatory mechanisms. Oncogene. 28:2925–2939. 2009. View Article : Google Scholar : PubMed/NCBI
|
44
|
Perdiguero E and Nebreda AR: Regulation of
Cdc25C activity during the meiotic G2/M transition. Cell Cycle.
3:733–737. 2004. View Article : Google Scholar : PubMed/NCBI
|
45
|
Hu X and Moscinski LC: Cdc2: A monopotent
or pluripotent CDK? Cell Prolif. 44:205–211. 2011. View Article : Google Scholar : PubMed/NCBI
|
46
|
Berridge MJ: Inositol trisphosphate and
calcium signalling. Nature. 361:315–325. 1993. View Article : Google Scholar : PubMed/NCBI
|